<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621724</url>
  </required_header>
  <id_info>
    <org_study_id>D-00272-CT2014001</org_study_id>
    <nct_id>NCT01621724</nct_id>
  </id_info>
  <brief_title>WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study</brief_title>
  <official_title>WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Medica Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cell Therapy Catapult</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cell Medica Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WT1 TCR gene therapy is a new treatment for acute myeloid leukaemia and chronic myeloid&#xD;
      leukaemia.&#xD;
&#xD;
      Patient's white blood cells (T cells) are modified to specifically fight the leukaemia cells&#xD;
      by transferring a gene into the T cells, which allows them to recognize fragments of a&#xD;
      protein called WT1. This protein is present on the surface of leukaemia cells at very high&#xD;
      levels. The gene transferred to the T cells enables them to make a new T cell receptor (TCR),&#xD;
      which will allow them to attack leukaemia cells with high levels of WT1 on their surface.&#xD;
&#xD;
      Using this form of gene therapy the investigators can convert some of the patient's immune&#xD;
      system's own T cells into T cells that the investigators hope will be much more effective at&#xD;
      recognizing and killing leukaemia cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial concerns a novel approach to generating leukaemia antigen-specific T cells for&#xD;
      adoptive cellular therapy in HLA-A*0201 patients with acute myeloid leukaemia (AML) and&#xD;
      chronic myeloid leukaemia (CML)&#xD;
&#xD;
      In this study, patient T cells will be gene-modified using a GMP grade retroviral vector&#xD;
      containing the genes for a WT1-specific, HLA-A2-restricted T cell receptor. This ex vivo gene&#xD;
      therapy will generate T cells expressing the WT1-specific TCR and thus able to recognise&#xD;
      WT1-expressing target cells.&#xD;
&#xD;
      The autologous Cys1 WT1 TCR-transduced T cells will be re-infused back into adult leukaemia&#xD;
      patients following lymphodepleting conditioning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify organ toxicities and other side effects</measure>
    <time_frame>Up to 12 months per patient</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transduction efficiency and TCR expression on TCR-transduced cells</measure>
    <time_frame>Up to 12 months per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>WT1-specific immune responses of TCR-transduced T cells</measure>
    <time_frame>Up to 12 months per patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <condition>Chronic Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>Single arm cohort study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WT1 TCR-transduced T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>WT1 TCR-transduced T cells</intervention_name>
    <description>Two patient cohorts:&#xD;
Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells&#xD;
Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells</description>
    <arm_group_label>Single arm cohort study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 75 years.&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks (4 months).&#xD;
&#xD;
          -  World Health Organisation (WHO) performance status of 0-2&#xD;
&#xD;
          -  HLA A*0201 positive&#xD;
&#xD;
          -  Completed previous course of chemotherapy ≥ 4 weeks prior to commencing the initial&#xD;
             phase of the trial (leucapheresis for collection of patient PBMC).&#xD;
&#xD;
          -  Peripheral blood total lymphocyte count &gt; 0.5x109/L.&#xD;
&#xD;
          -  Informed consent in writing and ability to co-operate with treatment and follow up.&#xD;
&#xD;
          -  Willing, able and available for collection of PBMC/ T cells by leucapheresis.&#xD;
&#xD;
          -  Hepatitis B and C, HTLV-1, Syphilis, HIV negative.&#xD;
&#xD;
          -  Free from serious concurrent illness.&#xD;
&#xD;
          -  Female patients of child-bearing age must have a negative pregnancy test and agree to&#xD;
             use reliable contraceptive methods for the duration of the therapy and for 6 months&#xD;
             afterwards.&#xD;
&#xD;
          -  Male patients must agree to use appropriate medically approved contraception during&#xD;
             the trial and for six months afterwards.&#xD;
&#xD;
          -  Haematological and Biochemical Indices:&#xD;
&#xD;
          -  Haemoglobin (Hb) ≥ 7.0 g/dl; neutrophils ≥ 0.2 x 109/L; total lymphocytes &gt; 0.5 x&#xD;
             109/L; platelets (Plts) ≥ 40 x 109/L&#xD;
&#xD;
          -  serum bilirubin, Alanine amino-transferase (ALT) and/or aspartate amino transferase&#xD;
             (AST) &lt; 3 x upper normal limit&#xD;
&#xD;
          -  calculated creatinine clearance ≥ 30 ml/min (uncorrected value) or isotope clearance&#xD;
             measurement ≥ 30ml/min&#xD;
&#xD;
        Further disease specific inclusion criteria are detailed in Protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years or &gt; 75 years.&#xD;
&#xD;
          -  Patients should not receive concurrent systemic corticosteroids whilst on the study.&#xD;
&#xD;
          -  Within three months of having received fludarabine (at time of leucapheresis).&#xD;
&#xD;
          -  Major thoracic and/or abdominal surgery in the preceding three to four weeks from&#xD;
             which the patient has not yet recovered.&#xD;
&#xD;
          -  Patients who are high medical risks because of non-malignant systemic disease, as well&#xD;
             as those with active uncontrolled infection.&#xD;
&#xD;
          -  Patients with any other condition, which in the Investigator's opinion would not make&#xD;
             the patient a good candidate for the clinical trial.&#xD;
&#xD;
          -  Patients known to be serologically positive for Hepatitis B, C, HTLV-1 Syphilis or&#xD;
             HIV.&#xD;
&#xD;
          -  Concurrent congestive heart failure or prior history of New York Heart Association&#xD;
             (NYHA) class III/ IV cardiac disease&#xD;
&#xD;
          -  Positive pregnancy test or reluctance to use contraception.&#xD;
&#xD;
          -  Pregnant and lactating women are excluded.&#xD;
&#xD;
          -  History of Severe Allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Morris, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS38 3AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>WT1 TCR</keyword>
  <keyword>AML</keyword>
  <keyword>CML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

